Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.